Ras Association Domain-Containing Protein 6 Proteins (RASSF6)

Human Ras Association Domain-Containing Protein 6 (RASSF6) interaction partners

1. RASSF6 increases unphosphorylated pRb and augments the interaction between pRb and E2F1. Moreover, RASSF6 induces TP73 target genes via pRb and E2F1 in a p53-negative background.

2. RASSF6 functions as a potential tumor suppressor in human breast cancer through activation of Hippo pathway.

3. RASSF6 is down-regulated and exhibits tumor suppressor activities in hepatocellular carcinoma.

4. Study reports the interaction of BCL-XL with RASSF6. BCL-XL inhibits the interaction between RASSF6 and MDM2 and suppresses p53 expression. Consequently, BCL-XL antagonizes RASSF6-mediated apoptosis. Thus, the inhibition of RASSF6-mediated apoptosis also underlies the prosurvival role of BCL-XL.

5. Data suggest that Ras-association domain family protein 6 (RASSF6) may serve as a candidate against tumor growth for sporadic colorectal cancer (sCRC).

6. RASSF6 and RASSF10 were frequently hypermethylated in the samples at the time of diagnosis of adult acute lymphoblastic leukemia patients

7. Overexpression or silencing of RASSF6 could partially reverse the effects of the overexpression or repression of miR-181a-5p on GC progress caused by activation of the MAKP pathway in vitro and in vivo.

8. Results suggest that down-regulation of RASSF2, and RASSF6 is a tumor-specific phenomenon and their inactivation through CpG island methylation may play important roles in gastric cardia carcinogenesis.

9. Mechanistic investigation shows that RASSF6 triggers p21(Cip1/Waf1) accumulation to induce G 1 cell cycle arrest and promote apoptosis upon exposure to pro-apoptotic agents, and both of these mechanisms appear to be mediated by activated JNK signaling.

10. RASSF6 expression is an independent biomarker of an unfavorable prognosis in patients with pancreatic ductal adenocarcinoma.

11. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.RASSF6 exhibits the highest frequency of inactivation in melanoma and in melanoma brain metastases.

12. downregulation of RASSF6 in highly metastatic nasopharyngeal carcinoma cells contributed to their treatment resistance

13. RASSF6-induced apoptosis partially depends on p53. RASSF6 binds MDM2 and facilitates its ubiquitination. RASSF6 depletion blocks the increase of p53 in response to UV exposure and up-regulation of p53 target genes.

14. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

15. Decreased expression of RASSF6 is associated with gastric cancer.

16. These findings indicate that RASSF6 is implicated in apoptosis in HeLa cells and that it triggers both caspase-dependent and caspase-independent pathways.

17. Demonstrates properties of a Ras effector and tumor suppressor but exhibits biological properties that are unique and distinct from those of other family members.

18. Sequencing revealed RASSF6 and RASSF10 were the only RASSF members with a high frequency of leukaemia-specific methylation.

19. activation of MST2 causes apoptosis through the Hippo pathway, as well as through a RASSF6-mediated pathway

Mouse (Murine) Ras Association Domain-Containing Protein 6 (RASSF6) interaction partners

1. RASSF6 expression in adipocytes is down-regulated by interaction with macrophages.

2. Demonstrates properties of a Ras effector and tumor suppressor but exhibits biological properties that are unique and distinct from those of other family members.